Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection
Status:
Completed
Trial end date:
2018-08-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and
antiviral activity of single and multiple ascending doses of SH229 in patients with chronic
hepatitis C Virus infection.